Cart
sales@molnova.com
Ranibizumab
CAS No. 347396-82-1
Ranibizumab( —— )
Catalog No. M22159 CAS No. 347396-82-1
Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 820 | In Stock |
|
| 10MG | 1311 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRanibizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionRanibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A.
-
DescriptionRanibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorVEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number347396-82-1
-
Formula Weight48 kDa
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Klettner A, et al.Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways.Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4523-7.
molnova catalog
related products
-
Pz-1
Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.
-
Anlotinib Dihydrochl...
Anlotinib also known as AL3818 is a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities.
-
Cediranib maleate
A highly potent, orally bioavailable, pan-VEGFR inibitor with IC50 of 1, 5, 3 nM for VEGFR1, 2, 3, respectively.
